Pillar Biosciences Partners with AstraZeneca to Accelerate Access to Liquid Biopsy Testing (September, 2024)
In September 2024, Pillar Biosciences announced a strategic partnership with AstraZeneca to expand laboratory access to molecular testing in Europe and the UK using rapid, affordable NGS-based liquid biopsy tumor profiling kits. The collaboration leverages Pillar’s oncoReveal™ liquid biopsy panels to deliver highly sensitive and specific tumor genetic varia